Cargando…

Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study

This study aimed to assess the prevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) total antibodies in the north, middle, and south regions of West Bank and the prevalence of SARS-CoV-2 specific antibodies (IgA, IgM, and IgG) in the Palestinian population. This was a cross-sec...

Descripción completa

Detalles Bibliográficos
Autores principales: Maraqa, Beesan, Basha, Walid, Khayyat, Rasha, Abdul-Hadi, Abdul-Rahman, Jabareen, Jurouh, Al-Shakhra, Kamal, Al-Kaila, Mai, Nazzal, Zaher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500452/
https://www.ncbi.nlm.nih.gov/pubmed/34624024
http://dx.doi.org/10.1371/journal.pone.0258255
_version_ 1784580451685367808
author Maraqa, Beesan
Basha, Walid
Khayyat, Rasha
Abdul-Hadi, Abdul-Rahman
Jabareen, Jurouh
Al-Shakhra, Kamal
Al-Kaila, Mai
Nazzal, Zaher
author_facet Maraqa, Beesan
Basha, Walid
Khayyat, Rasha
Abdul-Hadi, Abdul-Rahman
Jabareen, Jurouh
Al-Shakhra, Kamal
Al-Kaila, Mai
Nazzal, Zaher
author_sort Maraqa, Beesan
collection PubMed
description This study aimed to assess the prevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) total antibodies in the north, middle, and south regions of West Bank and the prevalence of SARS-CoV-2 specific antibodies (IgA, IgM, and IgG) in the Palestinian population. This was a cross-sectional study. The serological and epidemiological data of 1269 persons were assessed. Participants were selected randomly among primary health care center attendees in Palestine between November 1, 2020 and December 31, 2020. All serum samples were tested for total antibodies using an enzyme-linked immunosorbent assay (ELISA) test. IgM, IgG, and IgA-specific antibody titers were measured using ELISA. The overall prevalence (with 95% confidence intervals [CIs]) of SARS-CoV-2 total antibodies and specific antibodies were estimated. A multivariate regression model was used to assess the predictive factors for SARS-CoV-2-specific antibodies. The overall seroprevalence of SARS-CoV-2 antibodies was 24·0% (95% CI, 21·7%–26·5%). Seroprevalence was significantly higher among people living in south West Bank (adjusted Odds ratio [aOR], 2·22; 95% CI: 1·58–3·11), people who had COVID-19 symptoms (aOR, 3·92; 95% CI, 2·83–5·43), people with a COVID-19 contact history (aOR, 1·44; 95% CI, 1·03–2·03), patients with hypertension (aOR, 1·57; 95% CI, 1·06–2·33), and non-smokers (aOR, 0·47; 95% CI, 0·31–0·72). A total of 171 blood samples from SARS-CoV-2-positive patients were chosen at random for additional serological testing. Specific IgM, IgG, and IgA antibodies were positive in 14·0% (95% CI, 9·2%–20·2%), 88·3% (82·5%–92·7%), and 42·1% (34·6%–59·9%) of the samples, respectively. SARS-CoV-2 antibodies were common among PHC center attendees and were significantly associated to sex, smoking, and COVID-19 contact history. However, considering that almost three-quarters of this population remains susceptible, maintaining public health measures and encouraging access to immunization is critical in protecting this population.
format Online
Article
Text
id pubmed-8500452
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-85004522021-10-09 Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study Maraqa, Beesan Basha, Walid Khayyat, Rasha Abdul-Hadi, Abdul-Rahman Jabareen, Jurouh Al-Shakhra, Kamal Al-Kaila, Mai Nazzal, Zaher PLoS One Research Article This study aimed to assess the prevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) total antibodies in the north, middle, and south regions of West Bank and the prevalence of SARS-CoV-2 specific antibodies (IgA, IgM, and IgG) in the Palestinian population. This was a cross-sectional study. The serological and epidemiological data of 1269 persons were assessed. Participants were selected randomly among primary health care center attendees in Palestine between November 1, 2020 and December 31, 2020. All serum samples were tested for total antibodies using an enzyme-linked immunosorbent assay (ELISA) test. IgM, IgG, and IgA-specific antibody titers were measured using ELISA. The overall prevalence (with 95% confidence intervals [CIs]) of SARS-CoV-2 total antibodies and specific antibodies were estimated. A multivariate regression model was used to assess the predictive factors for SARS-CoV-2-specific antibodies. The overall seroprevalence of SARS-CoV-2 antibodies was 24·0% (95% CI, 21·7%–26·5%). Seroprevalence was significantly higher among people living in south West Bank (adjusted Odds ratio [aOR], 2·22; 95% CI: 1·58–3·11), people who had COVID-19 symptoms (aOR, 3·92; 95% CI, 2·83–5·43), people with a COVID-19 contact history (aOR, 1·44; 95% CI, 1·03–2·03), patients with hypertension (aOR, 1·57; 95% CI, 1·06–2·33), and non-smokers (aOR, 0·47; 95% CI, 0·31–0·72). A total of 171 blood samples from SARS-CoV-2-positive patients were chosen at random for additional serological testing. Specific IgM, IgG, and IgA antibodies were positive in 14·0% (95% CI, 9·2%–20·2%), 88·3% (82·5%–92·7%), and 42·1% (34·6%–59·9%) of the samples, respectively. SARS-CoV-2 antibodies were common among PHC center attendees and were significantly associated to sex, smoking, and COVID-19 contact history. However, considering that almost three-quarters of this population remains susceptible, maintaining public health measures and encouraging access to immunization is critical in protecting this population. Public Library of Science 2021-10-08 /pmc/articles/PMC8500452/ /pubmed/34624024 http://dx.doi.org/10.1371/journal.pone.0258255 Text en © 2021 Maraqa et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Maraqa, Beesan
Basha, Walid
Khayyat, Rasha
Abdul-Hadi, Abdul-Rahman
Jabareen, Jurouh
Al-Shakhra, Kamal
Al-Kaila, Mai
Nazzal, Zaher
Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study
title Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study
title_full Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study
title_fullStr Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study
title_full_unstemmed Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study
title_short Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study
title_sort prevalence of sars-cov-2 antibodies in the palestinian population: a primary health center-based cross-sectional study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500452/
https://www.ncbi.nlm.nih.gov/pubmed/34624024
http://dx.doi.org/10.1371/journal.pone.0258255
work_keys_str_mv AT maraqabeesan prevalenceofsarscov2antibodiesinthepalestinianpopulationaprimaryhealthcenterbasedcrosssectionalstudy
AT bashawalid prevalenceofsarscov2antibodiesinthepalestinianpopulationaprimaryhealthcenterbasedcrosssectionalstudy
AT khayyatrasha prevalenceofsarscov2antibodiesinthepalestinianpopulationaprimaryhealthcenterbasedcrosssectionalstudy
AT abdulhadiabdulrahman prevalenceofsarscov2antibodiesinthepalestinianpopulationaprimaryhealthcenterbasedcrosssectionalstudy
AT jabareenjurouh prevalenceofsarscov2antibodiesinthepalestinianpopulationaprimaryhealthcenterbasedcrosssectionalstudy
AT alshakhrakamal prevalenceofsarscov2antibodiesinthepalestinianpopulationaprimaryhealthcenterbasedcrosssectionalstudy
AT alkailamai prevalenceofsarscov2antibodiesinthepalestinianpopulationaprimaryhealthcenterbasedcrosssectionalstudy
AT nazzalzaher prevalenceofsarscov2antibodiesinthepalestinianpopulationaprimaryhealthcenterbasedcrosssectionalstudy